References
- Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entitiy associated with the human immunodeficiency virus infection. Blood 1997;89:1413–1420.
- Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. Sci World J 2011;11:687–696.
- Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow S, Campo E, Harris NL, et al, editors. WHO classification of tumors of the hematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008. p 256–257.
- Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95:1342–1349.
- Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency vius-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118:5270–5277.
- Schommers P, Wyen C, Hentrich M, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013;27:842–845.
- Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. Leuk Lymphoma 2015;56:267–269.
- Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 200;107:3832–3840.
- Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009;115: 4540–4546.
- Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
- Moureau P, Pylypenko H, Grosick S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randmised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431–440.
- Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and incombination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010;28:e704–708.
- Saba N, Dang D, Saba J, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie 2013;36:287–291.
- Cao C, Liu T, Zhu H, et al. Bortezomib-contained chemotherapy and thalidomide combine with CHOP (Cyclophophamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in paslmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk 2014;14:e145–150.
- Castillo JJ, Reagan JL, Sikov WM, et al. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 2015;169:352–355.